FDA Approves New Drug for Metastatic Pancreatic Cancer
💡 Why it matters
This new pill could dramatically improve survival rates for the thousands of patients diagnosed annually with pancreatic cancer, which has a five-year survival rate of just 12%.
The FDA granted expedited approval to daraxonrasib, a first-in-class targeted therapy for metastatic pancreatic cancer. The drug blocks the mutated KRAS protein found in over 90% of pancreatic cancer cases.
Want more context?
Help us choose what to research next.
📡 Where we spotted it (2)
Hacker News
FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer
61d ago
›
The Guardian
FDA gives expedited approval to new groundbreaking pancreatic cancer drug
61d ago
›